Baidu
map

Blood:CSF1R抑制剂通过阻断支持细胞的旁分泌信号抑制急性髓系白血病细胞

2018-11-14 MedSci MedSci原创

中心点:CSF1R在支持细胞亚群中表达,其抑制可降低超过20%的AML患者样本的细胞活性。CSF1R活性刺激旁路细胞因子分泌,或可作为AML支持细胞的新治疗靶点。摘要:为明确AML的新的治疗靶点,研究人员对原发性AML患者样本进行小分子和siRNA筛选。在23%的样本中,研究人员发现了对CSF1R抑制的敏感性,CSF1R是一种受体酪氨酸激酶,调控髓系细胞的存活、增殖和分化。对CSF1R抑制剂GW-

中心点:

CSF1R在支持细胞亚群中表达,其抑制可降低超过20%的AML患者样本的细胞活性。

CSF1R活性刺激旁路细胞因子分泌,或可作为AML支持细胞的新治疗靶点。

摘要:

为明确AML的新的治疗靶点,研究人员对原发性AML患者样本进行小分子和siRNA筛选。在23%的样本中,研究人员发现了对CSF1R抑制的敏感性,CSF1R是一种受体酪氨酸激酶,调控髓系细胞的存活、增殖和分化。对CSF1R抑制剂GW-2580的敏感性优先在新生和有利的风险患者中发现,对GW-2580耐受与整体生存率降低相关。

通过流式细胞术,研究人员发现CSF1R不是在大多数白血病细胞中表达,而是在支持细胞亚群中表达。通过大量细胞计数法(CyTOF)对比AML患者和健康供体的CSF1R表达细胞,结果发现CSF1R是独特的细胞表面标志物。

CSF1R表达细胞数量与GW-2580敏感性相关。将原发性AML患者样本暴露于一组重组细胞因子中,发现CSF1R抑制剂敏感性与对CSF1R配体、CSF1和其他细胞因子(包括HGF,另一种生长因子)的生长反应相关。添加CSF1可增加AML患者样本条件性培养基中HGF和其他细胞因子的分泌,加入GW-2580则可抑制其分泌。在未处理过的细胞中,HGF水平与GW-2580敏感性显著相关。最后,重组HGF和HS-5条件性培养基可恢复GW-2580处理过的AML患者样本的细胞活性。

综上所述,本研究表明CSF1R表达细胞通过分泌HGF和其他细胞因子来支持白血病细胞,提示CSF1R或可作为AML的新的治疗靶点,揭示了旁路细胞因子/生长因子分泌信号在该疾病中的作用机制。


原始出处:

David K. Edwards V,et al.CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood  2018  :blood-2018-03-838946;  doi: https://doi.org/10.1182/blood-2018-03-838946

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-09-17 gwc392
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-03-28 kcb078
  6. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-04-19 jklm09
  7. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-08-24 839640778
  8. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-11-15 lfcmxl
  10. [GetPortalCommentsPageByObjectIdResponse(id=1822075, encodeId=eefd18220e5d7, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Wed Apr 03 17:51:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078718, encodeId=44fe20e871889, content=<a href='/topic/show?id=0f145e0833a' target=_blank style='color:#2F92EE;'>#支持细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57083, encryptionId=0f145e0833a, topicName=支持细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Mar 28 09:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710168, encodeId=cef51e1016893, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 12 22:51:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682477, encodeId=3caa16824e744, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Sep 17 03:51:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668853, encodeId=4a4c16688531e, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Thu Mar 28 01:51:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851841, encodeId=280b1851841fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Apr 19 04:51:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783855, encodeId=09501e838557a, content=<a href='/topic/show?id=ddc15341d3' target=_blank style='color:#2F92EE;'>#CSF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5341, encryptionId=ddc15341d3, topicName=CSF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 24 19:51:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082060, encodeId=a7472082060a8, content=<a href='/topic/show?id=73c95342e9' target=_blank style='color:#2F92EE;'>#CSF1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5342, encryptionId=73c95342e9, topicName=CSF1R)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sun Feb 17 03:51:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629916, encodeId=3cc616299165c, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Thu Nov 15 23:51:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352663, encodeId=d36e352663e5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75e72464368, createdName=598674564_99925145, createdTime=Thu Nov 15 11:53:43 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-11-15 598674564_99925145

    学习

    0

相关资讯

CLIN CANCER RES:CSF1R基因改变通过改变巨噬细胞功能调节肿瘤免疫

通过抑制集落刺激因子1(CSF-1R)靶向肿瘤相关巨噬细胞是肿瘤治疗的策略之一。CLIN CANCER RES近期发表了一篇文章,研究CSF1R基因改变对CSF-1R信号以及CSF-1R抑制剂敏感性的影响。

Cancer cell:那些促进肿瘤生长,还吃PD-1抗体的巨噬细胞,科学家终于找到消灭你的好办法了

近年来的研究就发现,在肿瘤中总重量的50%竟然是巨噬细胞。这些肿瘤相关巨噬细胞(Tumor-associated macrophage, TAM)不仅会阻止T细胞攻击肿瘤细胞,而且还会分泌生长因子滋养肿瘤细胞,促进肿瘤血管的生成,导致肿瘤细胞转移扩散。

Baidu
map
Baidu
map
Baidu
map